MiR-155 contributes to intestinal barrier dysfunction in DSS-induced mice colitis via targeting HIF-1α/TFF-3 axis

Liu, Yujin; Zhu, Feng; Li, Huarong; Fan, Huiying; Wu, Hui; Dong, Yalan; Chu, Si; Tan, Chen; Wang, Quansheng; He, Hongqing; Gao, Fei; Leng, Xue-Yuan; Zhou, Qilai; Zhu, Xiwen

doi:10.18632/aging.103555

Cited by 31 publications

(27 citation statements)

References 44 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, mitochondria are not the only membranous organelles that alter shape and physiology upon colitis. Our previous study, in addition to reports by other authors, revealed the abnormal shape of multiple membranous organelles, including mitochondria, endoplasmic reticulum (ER) and Golgi apparatuses, and cellular and nuclear membranes during inflammation [ 37 , 38 , 39 , 45 , 46 , 47 ]. These indicate that membrane-forming phospholipids may be substantially deregulated upon colitis, which is further supported by experimental data [ 48 , 49 , 50 ].…”

Section: Introductionmentioning

confidence: 61%

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

Boldyreva

Морозова

Saydakova³

et al. 2021

IJMS

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) comprise a distinct set of clinical symptoms resulting from chronic inflammation within the gastrointestinal (GI) tract. Despite the significant progress in understanding the etiology and development of treatment strategies, IBD remain incurable for thousands of patients. Metabolic deregulation is indicative of IBD, including substantial shifts in lipid metabolism. Recent data showed that changes in some phospholipids are very common in IBD patients. For instance, phosphatidylcholine (PC)/phosphatidylethanolamine (PE) and lysophosphatidylcholine (LPC)/PC ratios are associated with the severity of the inflammatory process. Composition of phospholipids also changes upon IBD towards an increase in arachidonic acid and a decrease in linoleic and a-linolenic acid levels. Moreover, an increase in certain phospholipid metabolites, such as lysophosphatidylcholine, sphingosine-1-phosphate and ceramide, can result in enhanced intestinal inflammation, malignancy, apoptosis or necroptosis. Because some phospholipids are associated with pathogenesis of IBD, they may provide a basis for new strategies to treat IBD. Current attempts are aimed at controlling phospholipid and fatty acid levels through the diet or via pharmacological manipulation of lipid metabolism.

show abstract

Section: Introductionmentioning

confidence: 61%

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

Boldyreva

Морозова

Saydakova³

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…MiR-155 promotes intestinal inflammation in UC and CD, probably via a variety of inflammation-related pathways [46,56,73,79,81,139]. In a recent study by Liu et al [144,145], it was shown that miR-155 mediates intestinal barrier dysfunction in DSS-induced mice colitis through targeting the HIF-1α/TFF-3 axis. Paraskevi et al [140] found that miR-155 is the most highly expressed UC-associated miRNA in blood samples, however, in the study by Schönauen [47], the authors did not find increased miR-155 levels in the blood from IBD patients, suggesting that more studies are needed to determine whether miR-155 is a putative blood-related biomarker.…”

Section: Mirnas and Cacmentioning

confidence: 99%

MicroRNA Biomarkers in IBD—Differential Diagnosis and Prediction of Colitis-Associated Cancer

James

Riis

Malham

et al. 2020

IJMS

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). These are chronic autoimmune diseases of unknown etiology affecting the gastrointestinal tract. The IBD population includes a heterogeneous group of patients with varying disease courses requiring personalized treatment protocols. The complexity of the disease often delays the diagnosis and the initiation of appropriate treatments. In a subset of patients, IBD leads to colitis-associated cancer (CAC). MicroRNAs are single-stranded regulatory noncoding RNAs of 18 to 22 nucleotides with putative roles in the pathogenesis of IBD and colorectal cancer. They have been explored as biomarkers and therapeutic targets. Both tissue-derived and circulating microRNAs have emerged as promising biomarkers in the differential diagnosis and in the prognosis of disease severity of IBD as well as predictive biomarkers in drug resistance. In addition, knowledge of the cellular localization of differentially expressed microRNAs is a prerequisite for deciphering the biological role of these important epigenetic regulators and the cellular localization may even contribute to an alternative repertoire of biomarkers. In this review, we discuss findings based on RT-qPCR, microarray profiling, next generation sequencing and in situ hybridization of microRNA biomarkers identified in the circulation and in tissue biopsies.

show abstract

“…It increases IL-8 throughout the inflammatory process [ 78 , 79 ], modulates the inflammatory phenotype of intestinal fibroblasts and myofibroblasts via NF-κB [ 80 ]. A recent study showed that miR-155 mediates intestinal barrier dysfunction in DSS-induced mice colitis through HIF1α/TFF-3 axis [ 81 ]. The knock-down of miR-155 protects the experimental colitis mice by decreasing IFNγ, TNFα, IL-6, IL-12 and IL-17 production, reducing Th1 response and suppressing the T-cells activation by DCs [ 82 ].…”

Section: Micrornas Overexpression Induces Colitis-associated Colorectal Carcinogenesismentioning

confidence: 99%

The Role of microRNAs in Development of Colitis-Associated Colorectal Cancer

Bocchetti

Ferraro

Ricciardiello

et al. 2021

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most deadly cancer worldwide, and inflammatory bowel disease (IBD) is one of the critical factors in CRC carcinogenesis. IBD is responsible for an unphysiological and sustained chronic inflammation environment favoring the transformation. MicroRNAs (miRNAs) belong to a class of highly conserved short single-stranded segments (18–25 nucleotides) non-coding RNA and have been extensively discussed in both CRC and IBD. However, the role of miRNAs in the development of colitis-associated CRC (CAC) is less clear. The aim of this review is to summarize the major upregulated (miR-18a, miR-19a, miR-21, miR-31, miR-155 and miR-214) and downregulated (miR-124, miR-193a-3p and miR-139-5p) miRNAs in CAC, and their roles in genes’ expression modulation in chronic colonic-inflammation-induced carcinogenesis, including programmed cell-death pathways. These miRNAs dysregulation could be applied for early CAC diagnosis, to predict therapy efficacy and for precision treatment.

show abstract

MiR-155 contributes to intestinal barrier dysfunction in DSS-induced mice colitis via targeting HIF-1α/TFF-3 axis

Cited by 31 publications

References 44 publications

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

Fat of the Gut: Epithelial Phospholipids in Inflammatory Bowel Diseases

MicroRNA Biomarkers in IBD—Differential Diagnosis and Prediction of Colitis-Associated Cancer

The Role of microRNAs in Development of Colitis-Associated Colorectal Cancer

Contact Info

Product

Resources

About